Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (SHA:600866)
China · Delayed Price · Currency is CNY 5.12
+0.11 (2.20%)
Jun 1, 2026, 3:00 PM CST
SHA:600866 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 14,993 | 15,293 | 16,710 | 16,891 | 17,074 | 3,970 |
Other Revenue | 607.51 | 607.51 | 624.13 | 482.72 | 412.8 | 100.95 |
| 15,601 | 15,900 | 17,334 | 17,374 | 17,486 | 4,071 | |
Revenue Growth (YoY) | -9.16% | -8.27% | -0.23% | -0.64% | 329.51% | 264.72% |
Cost of Revenue | 13,672 | 13,350 | 14,393 | 14,976 | 14,488 | 3,276 |
Gross Profit | 1,929 | 2,550 | 2,942 | 2,397 | 2,998 | 794.87 |
Selling, General & Admin | 1,118 | 1,071 | 1,076 | 947.17 | 935.84 | 365.04 |
Research & Development | 176.59 | 182.02 | 169.78 | 179.31 | 177.98 | 98.83 |
Other Operating Expenses | 107.91 | 107.18 | 104.97 | 80.35 | 118.9 | 8.21 |
Operating Expenses | 1,404 | 1,370 | 1,346 | 1,213 | 1,236 | 469.21 |
Operating Income | 524.89 | 1,180 | 1,596 | 1,185 | 1,762 | 325.66 |
Interest Expense | -74.36 | -80.71 | -109.68 | -173.46 | -243.29 | -83.35 |
Interest & Investment Income | 57.26 | 52.01 | 14.85 | 21.43 | 15.5 | 7.26 |
Currency Exchange Gain (Loss) | 21.41 | 21.41 | 37.4 | -8.33 | -76.91 | 6.6 |
Other Non Operating Income (Expenses) | -25.72 | -5.64 | -19.65 | -14.12 | -40.35 | 4.97 |
EBT Excluding Unusual Items | 503.48 | 1,167 | 1,519 | 1,010 | 1,417 | 261.14 |
Impairment of Goodwill | - | - | -91.91 | -93.7 | -12.34 | - |
Gain (Loss) on Sale of Investments | 5.82 | 20.78 | -237.67 | -66.94 | 3.6 | 8.79 |
Gain (Loss) on Sale of Assets | -5.28 | -5.29 | 28.69 | 0.3 | 4.35 | 0.83 |
Asset Writedown | 0.88 | -13.36 | -6.9 | -14.15 | -17.14 | -4.31 |
Other Unusual Items | 69.13 | 49.42 | 21.92 | 27.88 | 27.72 | 11.81 |
Pretax Income | 574.03 | 1,218 | 1,233 | 863.62 | 1,424 | 278.26 |
Income Tax Expense | 124.85 | 248.21 | 283.27 | 177.92 | 240.56 | 29.18 |
Earnings From Continuing Operations | 449.18 | 970.04 | 949.81 | 685.7 | 1,183 | 249.07 |
Minority Interest in Earnings | 8.65 | 8.85 | -6.66 | -7.74 | -574.66 | -96.94 |
Net Income | 457.83 | 978.89 | 943.15 | 677.95 | 608.33 | 152.14 |
Net Income to Common | 457.83 | 978.89 | 943.15 | 677.95 | 608.33 | 152.14 |
Net Income Growth | -60.73% | 3.79% | 39.12% | 11.45% | 299.85% | 2.31% |
Shares Outstanding (Basic) | 1,662 | 1,661 | 1,661 | 1,662 | 1,188 | 807 |
Shares Outstanding (Diluted) | 1,662 | 1,661 | 1,661 | 1,662 | 1,188 | 807 |
Shares Change (YoY) | 0.02% | 0.00% | -0.02% | 39.91% | 47.23% | 9.14% |
EPS (Basic) | 0.28 | 0.59 | 0.57 | 0.41 | 0.51 | 0.19 |
EPS (Diluted) | 0.28 | 0.59 | 0.57 | 0.41 | 0.51 | 0.19 |
EPS Growth | -60.74% | 3.79% | 39.14% | -20.34% | 171.58% | -6.26% |
Free Cash Flow | -1,883 | -746.52 | 1,759 | 1,650 | 1,210 | -181.59 |
Free Cash Flow Per Share | -1.13 | -0.45 | 1.06 | 0.99 | 1.02 | -0.23 |
Dividend Per Share | 0.380 | 0.380 | 0.380 | 0.380 | - | - |
Gross Margin | 12.36% | 16.04% | 16.97% | 13.80% | 17.15% | 19.52% |
Operating Margin | 3.36% | 7.42% | 9.21% | 6.82% | 10.08% | 8.00% |
Profit Margin | 2.94% | 6.16% | 5.44% | 3.90% | 3.48% | 3.74% |
Free Cash Flow Margin | -12.07% | -4.70% | 10.15% | 9.50% | 6.92% | -4.46% |
EBITDA | 1,357 | 2,013 | 2,434 | 2,035 | 2,742 | 429.11 |
EBITDA Margin | 8.70% | 12.66% | 14.04% | 11.71% | 15.68% | 10.54% |
D&A For EBITDA | 831.94 | 833.19 | 838.18 | 850.63 | 979.49 | 103.45 |
EBIT | 524.89 | 1,180 | 1,596 | 1,185 | 1,762 | 325.66 |
EBIT Margin | 3.36% | 7.42% | 9.21% | 6.82% | 10.08% | 8.00% |
Effective Tax Rate | 21.75% | 20.38% | 22.97% | 20.60% | 16.90% | 10.49% |
Revenue as Reported | 15,601 | 15,900 | 17,334 | 17,374 | 17,486 | 4,071 |
Advertising Expenses | - | 20 | 51.05 | 62.42 | 17.7 | 4.96 |